JP2021518138A5 - - Google Patents

Info

Publication number
JP2021518138A5
JP2021518138A5 JP2020550713A JP2020550713A JP2021518138A5 JP 2021518138 A5 JP2021518138 A5 JP 2021518138A5 JP 2020550713 A JP2020550713 A JP 2020550713A JP 2020550713 A JP2020550713 A JP 2020550713A JP 2021518138 A5 JP2021518138 A5 JP 2021518138A5
Authority
JP
Japan
Prior art keywords
seq
cdr2
heavy chain
nos
antigen
Prior art date
Application number
JP2020550713A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019183499A5 (https=
JP2021518138A (ja
JP7328983B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023625 external-priority patent/WO2019183499A1/en
Publication of JP2021518138A publication Critical patent/JP2021518138A/ja
Publication of JPWO2019183499A5 publication Critical patent/JPWO2019183499A5/ja
Publication of JP2021518138A5 publication Critical patent/JP2021518138A5/ja
Priority to JP2023078028A priority Critical patent/JP7742377B2/ja
Application granted granted Critical
Publication of JP7328983B2 publication Critical patent/JP7328983B2/ja
Priority to JP2024185935A priority patent/JP7766162B2/ja
Priority to JP2025181096A priority patent/JP2026016604A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550713A 2018-03-22 2019-03-22 抗il-27抗体及びその使用 Active JP7328983B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023078028A JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用
JP2024185935A JP7766162B2 (ja) 2018-03-22 2024-10-22 抗il-27抗体及びその使用
JP2025181096A JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862646496P 2018-03-22 2018-03-22
US62/646,496 2018-03-22
PCT/US2019/023625 WO2019183499A1 (en) 2018-03-22 2019-03-22 Anti-il-27 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023078028A Division JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用

Publications (4)

Publication Number Publication Date
JP2021518138A JP2021518138A (ja) 2021-08-02
JPWO2019183499A5 JPWO2019183499A5 (https=) 2022-03-30
JP2021518138A5 true JP2021518138A5 (https=) 2022-03-30
JP7328983B2 JP7328983B2 (ja) 2023-08-17

Family

ID=67987990

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020550713A Active JP7328983B2 (ja) 2018-03-22 2019-03-22 抗il-27抗体及びその使用
JP2023078028A Active JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用
JP2024185935A Active JP7766162B2 (ja) 2018-03-22 2024-10-22 抗il-27抗体及びその使用
JP2025181096A Pending JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023078028A Active JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用
JP2024185935A Active JP7766162B2 (ja) 2018-03-22 2024-10-22 抗il-27抗体及びその使用
JP2025181096A Pending JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Country Status (13)

Country Link
US (3) US11332524B2 (https=)
EP (1) EP3768317A4 (https=)
JP (4) JP7328983B2 (https=)
KR (2) KR102879521B1 (https=)
CN (3) CN120463807A (https=)
AU (1) AU2019239324A1 (https=)
BR (1) BR112020018918A2 (https=)
CA (1) CA3093740A1 (https=)
IL (2) IL326896A (https=)
MA (1) MA52094A (https=)
MX (2) MX2020009879A (https=)
SG (1) SG11202008707YA (https=)
WO (1) WO2019183499A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120463807A (zh) 2018-03-22 2025-08-12 表面肿瘤学有限责任公司 抗il-27抗体及其用途
BR112021011393A2 (pt) * 2018-12-13 2021-08-31 Surface Oncology, Inc. Anticorpos anti-il-27 e usos dos mesmos
MX2022003719A (es) * 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
US12240897B2 (en) * 2020-09-22 2025-03-04 Institute For Cancer Research Treatment of non-alcoholic steatohepatitis (NASH) with IL-27 antibody
US12577299B2 (en) * 2021-05-07 2026-03-17 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
WO2023230116A1 (en) * 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
WO2023230128A1 (en) * 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US7148330B2 (en) 1999-07-30 2006-12-12 Schering Corporation Binding compounds for IL-27
CA2443862A1 (en) * 2001-04-17 2002-10-24 Peizhi Luo Structure-based construction of human antibody library
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CA2555421A1 (en) * 2004-02-17 2005-09-01 Schering Corporation Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB-特异性抗体及其使用方法
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP1987837A1 (en) 2007-05-02 2008-11-05 Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus Pharmaceutical composition for increasing insulin secretion from pancreatic ß-cells
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011133931A1 (en) * 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
AU2012205384B2 (en) 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
US20150284459A1 (en) 2012-10-31 2015-10-08 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI695011B (zh) * 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
EP3916017A1 (en) 2014-12-22 2021-12-01 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN120463807A (zh) 2018-03-22 2025-08-12 表面肿瘤学有限责任公司 抗il-27抗体及其用途

Similar Documents

Publication Publication Date Title
JP2021518138A5 (https=)
JP7569166B2 (ja) Pd-1に対する抗体分子およびその使用
AU2019320336B2 (en) Combination of antibody-drug conjugate and tubulin inhibitor
CN106573977B (zh) 针对ceacam1的人源化抗体
JP2021113220A (ja) Pd−l1アンタゴニスト併用療法
CN113195000A (zh) 抗体-药物缀合物和激酶抑制剂的组合
JP2018522027A (ja) Pd−1に対する抗体分子を含む組み合わせ治療
KR20170003575A (ko) 비-소세포 폐암을 치료하기 위한 항-b7-h1 및 항-ctla-4 항체
CN108623685A (zh) 抗ox40抗体及其用途
JP7606706B2 (ja) ヒトネクチン-2に特異的な抗体
JP2025011315A5 (https=)
CN113677707A (zh) 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
JP2023548051A (ja) 肺がんのためのlag-3アンタゴニスト療法
CN114340679A (zh) 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物
JP2025507694A (ja) 結腸直腸癌に対する組み合わせ療法
JPWO2019183499A5 (https=)
IL309227A (en) LAG-3 antagonist therapy for hematological cancer
JPWO2020123011A5 (https=)
JP2025542297A (ja) 肺癌の組み合わせ療法
JPWO2021062244A5 (https=)
RU2788092C2 (ru) Молекулы антител к pd-1 и их применения
WO2025245489A1 (en) Treatment of tumors in subjects having fgl-1 positive samples
CN116568307A (zh) 用于肺癌的lag-3拮抗剂疗法
HK40043732A (en) Combination of antibody-drug conjugate and tubulin inhibitor
HK40063551A (en) Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor